CN103768010A - 采用磺丁基-β-环糊精配制高浓度四氢化萘类化合物均一稳定溶液的方法 - Google Patents
采用磺丁基-β-环糊精配制高浓度四氢化萘类化合物均一稳定溶液的方法 Download PDFInfo
- Publication number
- CN103768010A CN103768010A CN201210402980.9A CN201210402980A CN103768010A CN 103768010 A CN103768010 A CN 103768010A CN 201210402980 A CN201210402980 A CN 201210402980A CN 103768010 A CN103768010 A CN 103768010A
- Authority
- CN
- China
- Prior art keywords
- beta
- cyclodextrin
- solution
- sulphur
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 title abstract 5
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetraline Natural products C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims abstract description 46
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 33
- 239000001116 FEMA 4028 Substances 0.000 claims description 33
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 33
- 239000005864 Sulphur Substances 0.000 claims description 33
- 229960004853 betadex Drugs 0.000 claims description 33
- 239000012456 homogeneous solution Substances 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- -1 tetralin compound Chemical class 0.000 abstract 2
- 238000005303 weighing Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 32
- 239000000725 suspension Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 9
- 238000013329 compounding Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 5
- 241000224016 Plasmodium Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- QTYPWHKJEDCDNH-UHFFFAOYSA-N 2-[(tert-butylamino)methyl]-4-[(7-chloroquinolin-4-yl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C1CCCC2=C(O)C(CNC(C)(C)C)=CC(NC=3C4=CC=C(Cl)C=C4N=CC=3)=C21 QTYPWHKJEDCDNH-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 210000000973 gametocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210402980.9A CN103768010B (zh) | 2012-10-22 | 2012-10-22 | 采用磺丁基-β-环糊精配制高浓度四氢化萘类化合物均一稳定溶液的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210402980.9A CN103768010B (zh) | 2012-10-22 | 2012-10-22 | 采用磺丁基-β-环糊精配制高浓度四氢化萘类化合物均一稳定溶液的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103768010A true CN103768010A (zh) | 2014-05-07 |
CN103768010B CN103768010B (zh) | 2016-05-25 |
Family
ID=50561076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210402980.9A Active CN103768010B (zh) | 2012-10-22 | 2012-10-22 | 采用磺丁基-β-环糊精配制高浓度四氢化萘类化合物均一稳定溶液的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103768010B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104666300A (zh) * | 2014-07-04 | 2015-06-03 | 昆明制药集团股份有限公司 | 一种磷酸萘酚喹的新用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1800221A (zh) * | 2005-11-02 | 2006-07-12 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
CN1832734A (zh) * | 2003-07-26 | 2006-09-13 | 施瓦茨制药有限公司 | 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘 |
-
2012
- 2012-10-22 CN CN201210402980.9A patent/CN103768010B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1832734A (zh) * | 2003-07-26 | 2006-09-13 | 施瓦茨制药有限公司 | 用于治疗抑郁症的取代的2-氨基1,2,3,4-四氢化萘 |
CN1800221A (zh) * | 2005-11-02 | 2006-07-12 | 南京师范大学 | 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104666300A (zh) * | 2014-07-04 | 2015-06-03 | 昆明制药集团股份有限公司 | 一种磷酸萘酚喹的新用途 |
CN104666300B (zh) * | 2014-07-04 | 2017-01-18 | 昆药集团股份有限公司 | 一种磷酸萘酚喹的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN103768010B (zh) | 2016-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fathalla et al. | In-vitro and in-vivo evaluation of niosomal gel containing aceclofenac for sustained drug delivery | |
JP6094388B2 (ja) | ペメトレキセドを含む注射用組成物 | |
US9949946B2 (en) | Inclusion complexes of pinocembrin with cyclodextrin or its derivatives | |
RU2016106124A (ru) | Соли дасатиниба в аморфной форме | |
US11266671B2 (en) | Compositions of O-glycosyl flavonoids | |
FI2662094T3 (fi) | Syklodekstriinin kompleksointimenetelmiä peptidiproteasomiestäjien formulointiin | |
WO2010045281A3 (en) | Stable aqueous formulations of water insoluble or poorly soluble drugs | |
CN104274398A (zh) | 一种含阿苯达唑悬浮剂及其制备方法 | |
JP5723031B2 (ja) | エキノカンジン系抗真菌剤であるミカファンギンを含む液体薬用組成物 | |
CN103690968A (zh) | 一种伏立康唑组合物及其制备方法 | |
CN101239040B (zh) | 雷公藤红素脂质体及其制备方法 | |
JP2020525516A (ja) | 注射用組成物 | |
CN102526036B (zh) | 一种含有丁苯酞和依达拉奉的复方注射液及制备方法 | |
CN103768010A (zh) | 采用磺丁基-β-环糊精配制高浓度四氢化萘类化合物均一稳定溶液的方法 | |
CN104844625A (zh) | 头孢孟多酯钠的一种新晶型及其结晶制备方法 | |
CN103768043B (zh) | 采用羟丙基-β-环糊精配制四氢化萘类化合物均一稳定溶液的方法 | |
CN105435221B (zh) | 一种针对血管内皮生长因子的人源化抗体的药物组合物 | |
JP5922609B2 (ja) | 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性組成物 | |
CN105106108A (zh) | 超分子控缓释型水杨酸配方及其制备技术 | |
CN101690547A (zh) | 一种液体多种维生素及其生产方法 | |
CN102115484B (zh) | 一种两性霉素b降解产物、其制备方法及其应用 | |
CN102274171A (zh) | 一种奥沙利铂注射剂 | |
CN116370407A (zh) | 包含4-((2-羟基-3-甲氧基苯甲醇)氨基)苯磺酰胺衍生物的水性肠道外药物制剂 | |
WO2014198342A1 (en) | Pharmaceutical composition comprising amorphous sunitinib | |
JP2010047482A (ja) | エダラボン注射液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: No. 1318 Wuzhong District Wuzhong road in Suzhou city of Jiangsu Province in 215104 Applicant after: Suzhou medicine bright Kant's new drug development limited company Applicant after: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. Applicant after: Tianjin Yaoming Kangde New Medicine Development Co., Ltd. Address before: No. 1318 Wuzhong District Wuzhong road in Suzhou city of Jiangsu Province in 215104 Applicant before: Suzhou AppTec Co., Ltd. Applicant before: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. Applicant before: Tianjin Yaoming Kangde New Medicine Development Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SUZHOU APPTEC CO., LTD. TO: SUZHOU YAOMING KANGDE NEW DRUG DEVELOPMENT CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160412 Address after: No. 1318 Wuzhong District Wuzhong road in Suzhou city of Jiangsu Province in 215104 Applicant after: Suzhou medicine bright Kant's new drug development limited company Address before: No. 1318 Wuzhong District Wuzhong road in Suzhou city of Jiangsu Province in 215104 Applicant before: Suzhou medicine bright Kant's new drug development limited company Applicant before: Shanghai Yaoming Kangde New Medicine Development Co., Ltd. Applicant before: Tianjin Yaoming Kangde New Medicine Development Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 215104 No. 1318 Wuzhong Avenue, Wuzhong District, Suzhou City, Jiangsu Province Patentee after: Suzhou AppTec Co., Ltd. Address before: 215104 No. 1318 Wuzhong Avenue, Wuzhong District, Suzhou City, Jiangsu Province Patentee before: Suzhou medicine bright Kant's new drug development limited company |